A recent clinical trial has demonstrated that a combination of the drugs finerenone and empagliflozin offers superior kidney protection in patients who suffer from both chronic kidney disease (CKD) and type 2 diabetes. The study, known as the CONFIDENCE trial, was funded by Bayer and registered under ClinicalTrials.gov number NCT05254002.
The trial focused on measuring reductions in the urinary albumin-to-creatinine ratio (UACR), a key marker of kidney damage. Participants who received both finerenone, a nonsteroidal mineralocorticoid receptor antagonist, and empagliflozin, an SGLT2 inhibitor, experienced greater improvements in UACR compared to those receiving either therapy alone.
This evidence suggests that the combination therapy provides an additive or synergistic benefit in slowing the progression of CKD in patients with coexisting type 2 diabetes. CKD and diabetes often coexist and significantly increase cardiovascular risk and mortality, making treatments that can effectively manage both conditions highly valuable.
These findings could have important implications for clinical practice, potentially leading to revised treatment guidelines for patients with these dual diagnoses. Further research may be necessary to assess long-term outcomes, including impacts on kidney function decline, dialysis initiation, and cardiovascular events.
The results present a promising advancement in the integrated management of chronic kidney disease and type 2 diabetes, pointing to the potential of combination pharmacotherapy in improving patient outcomes.
Source: https:// – Courtesy of the original publisher.
